Novo Nordisk executives believe that the company is on a path that will create growth in 2017 and beyond.
Pfizer is overcoming patent expirations by developing a steady new stream of products.
Roche’s Pharmaceuticals and Diagnostics Divisions continue to generate strong performances significantly driven by new product launches, including four new oncology treatments and the company’s first cancer immunotherapy medicine.
Sanofi executives continue to have faith in strategic plans to get the company to new heights despite continued impact from patent expirations.
Now on its seventh CEO in the last 10 years and in danger of losing its most valuable branded product, Teva is searching for answers.
HBA’s 2017 Annual Conference will be held in Philadelphia on Nov. 6-8, 2017.
A listing of the top 50 companies ranked by healthcare revenue.
A listing of the top 50 companies ranked by healthcare R&D spending
A listing of the top 50 companies ranked by consolidated revenue.
A listing of the top 50 companies ranked by net income.
